Human glioma immunobiology in vitro: Implications for immunogene therapy

Neurosurgery

Volumn 46, Issue 5, 2000, Pages 1169-1178

  Parney, Ian F ^a   Farr Jones, Maxine A ^a   Chang, Lung Ji ^a   Petruk, Kenneth C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cytokine; Glioma; Immunogene therapy; Immunology

Indexed keywords

CD86 ANTIGEN; FAS ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBIOLOGY; IMMUNOGENETICS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034018970     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-200005000-00030     Document Type: Article

References (69)

1. Allison JP: CD28-B7 interactions in T-cell activation. Curr Opin Immunol 6:414-419, 1994.
2. Ashley DM, Kong FM, Bigner DD, Hale LP: Endogenous expression of transforming growth factor betal inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 58:302-309, 1998.
3. Atkinson EA, Bleackley RC: Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 15:359-384, 1995.
4. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A: Immunosuppression and transforming growth factor-beta in glioblastoma: Preferential production of transforming growth factor-beta 2. J Immunol 143:3222-3229, 1989.
5. Brooks WH, Morford L, Shearer G, Zou J, Chougner C, Roszman T: Potential explanation for the immunodeficiency observed in patients with gliomas. Presented at the 12th International Conference on Brain Tumour Research and Therapy, Oxford, England, 1997.
6. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamazo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52:997-1007, 1983.
7. Chen C, Nabavi N: In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1:147-154, 1994.
8. Chen L, Linsley PS, Hellstrom KE: Costimulation of T cells for tumor immunity. Immunol Today 14:483-486, 1993.
9. Colombatti M, Bisconti M, Lorenzi P, Stevanoni G, Dipasquale B, Gerosa M, Tridente G: Human glioma cell lines: Tumour associated antigens distribution and sensitivity to antibody-toxin or ligand-toxin conjugates - A preliminary report. Acta Neurochir Suppl (Wien) 43:121-125, 1988.
10. Darmon AJ, Nicholson DW, Bleackley RC: Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377:446-448, 1995.
11. De Muralt B, de Tribolet N, Diserens AC, Stavrou D, Mach JP, Carrel S: Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma, and HLA-DR antigens. Eur J Cancer 21:207-216, 1985.
12. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Haurada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993.
13. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2909-2914, 1996.
14. Farr-Jones MA, Parney IF, Petruk KC: Improved technique for establishing short term human brain tumor cultures. J Neurooncol 43:1-10, 1999.
15. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance, and clinical relevance. Immunol Today 16:487-494, 1995.
16. Fine HA, Dear KBG, Loeffler JS, Black PMcL, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993.
17. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E: Production of prostaglandin E and interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413-2419, 1982.
18. Freeman GJ, Gribben JG, Baussioties VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T-cell proliferation. Science 262:909-911, 1993.
19. Frei K, Piani D, Malipiero UV, Van Meir E, de Tribolet N, Fontana A: Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells: Despite the presence of inducing signals, GM-CSF is not expressed in vivo. J Immunol 148: 3140-3146, 1992.
20. Galea-Lauri J, Farzaneh F, Gaken J: Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther 3:202-213, 1996.
21. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP: Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36:548-555, 1995.
22. Glick RP, Lichtor T, Mogharbel A, Taylor CA, Cohen EP: Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41:898-907, 1997.
23. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7:863-869, 1997.
24. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995.
25. Hanada K, Tsunoda R, Hamada H: GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity. J Leukoc Biol 60:181-190, 1996.
26. Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, Yagita H, Sato K, Okumura K: Human glioma-derived interleukin-10 inhibits anti-tumor immune responses in vitro. Neurosurgery 37:1160-1167, 1995.
27. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC: Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17:3217-3224, 1997.
28. Huettner C, Paulus W, Roggendorf W: Messenger RNA: Expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317-322, 1995.
29. Jaeckle KA: Immunotherapy of malignant gliomas. Semin Surg Oncol 21:249-259, 1994.
30. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530, 1994.
31. Kawamura T, Furue M: Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: Differential regulation by T helper type 1 and T helper type 2 cytokines. Eur J Immunol 25:1913-1917, 1995.
32. Kuppner M, Hamou M, Sawamura Y, Bodmer S, de Tribolet N: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71:211-217, 1989.
33. Lampson LA: Interpreting MHC class I expression and class I/class II reciprocity in the CNS: Reconciling divergent findings. Microsc Res Tech 32:267-285, 1995.
34. Lampson LA: Immunobiology of brain tumors: Antigens, effectors, and delivery to sites of microscopic tumor in the brain, in Black PMcL, Loeffler JS (eds): Cancer of the Nervous System. Cambridge, Blackwell Science, Inc., 1997, pp 874-906.
35. Lampson LA, Hickey WF: Monoclonal antibody analysis of MHC expression in human brain biopsies: Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136:4054-4062, 1986.
36. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 154:97-105, 1995.
37. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429, 1993.
38. Lichtor T, Libermann TA: Coexpression of interleukin-1 beta and interleukin-6 in human brain tumors. Neurosurgery 34:669-673, 1994.
39. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721-730, 1991.
40. Miyagi K, Ingram M, Techy GB, Jacques DB, Freshwater DB, Sheldon H: Immunohistochemical detection and correlation between MHC antigen and cell-mediated immune system in recurrent glioma by APAAP method. Neurol Med Chir (Tokyo) 30: 649-653, 1990.
41. Mizuno M, Yoshida J, Takaoka T, Sugita K: Liposomal transfection of human gamma-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells. J Neurosurg 80:510-514, 1994.
42. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138-146, 1996.
43. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S: Distribution of human Class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 44:4679-4687, 1984.
44. Nitta T, Hishii M, Sato K, Okamura K: Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649:122-128, 1994.
45. Parney IF, Petruk KC, Zhang C, Farr-Jones MA, Sykes DB, Chang L-J: GM-CSF and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse: Human glioblastoma multiforme model. Hum Gene Ther 8:1073-1085, 1997.
46. Rattis F-M, Peguet-Navarro J, Staquet M-J, Dezutter-Dambuyant C, Courtellemont P, Redziniak G, Schmitt D: Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Eur J Immunol 26:449-453, 1996.
47. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA: Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 14:182-190, 1993.
48. Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370-374, 1991.
49. 2+-indepedent T cell mediated cytotoxicity. J Exp Med 177:195-200, 1993.
50. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY: Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J Clin Invest 99:1173-1178, 1997.
51. Saito T, Tanaka R, Yoshida S, Washiyama K, Kumanishi T: Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors. Surg Neurol 29:435-442, 1988.
52. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93: 10399-10404, 1996.
53. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD: Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41:1365-1372, 1997.
54. Sawamura Y, Diserens A-C, de Tribolet N: In vitro Prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol 9:125-130, 1990.
55. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068, 1992.
56. Sheng WS, Hu S, Kravitz FH, Peterson PK, Chao CC: Tumor necrosis factor alpha upregulates human microglial cell production of interleukin-10 in vitro. Clin Diagn Lab Immunol 2:604-608, 1995.
57. Siepl C, Bodmer S, Frei K, MacDonald H, DeMartin R, Hofer E, Fontana A: The glioblastoma derived T-cell suppressor factor/ transforming growth factor beta 2 inhibits T-cell growth without affecting the interaction of interleukin-2 with its receptor. Eur J Immunol 18:593-600, 1988.
58. Studer A, de Tribolet N, Diserens AC, Gaide AC, Matthieu JM, Carrel S, Stavrou D: Characterization of four human malignant glioma cell lines. Acta Neuropathol (Berl) 66:208-217, 1985.
59. Tahara H, Lotze MT: Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96-106, 1995.
60. Thompson C: Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 71:979-982, 1995.
61. Trojan J, Duc HT, Upegui-Gonzalez LC, Hor F, Guo Y, Anthony D, Ilan J: Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 212:9-12, 1996.
62. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA: Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 181:775-779, 1995.
63. Van Meir E, Sawamura Y, Diserens A-C, Hamou M-F, de Tribolet N: Human glioblastoma cells release interleukin-6 in vivo and in vitro. Cancer Res 50:6683-6688, 1990.
64. Wagenknecht B, Gulbins E, Lang F, Dichgans J, Weller M: Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. FEBS Lett 409:17-23, 1997.
65. Weller M, Fontana A: The failure of current immunotherapy for malignant glioma: Tumor-derived TGF-B, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21:128-151, 1995.
66. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J Clin Invest 94:954-964, 1994.
67. Wu Y, Guo Y, Liu Y: A major costimulatory molecule on antigen-presenting cells, CTLA-4 ligand A, is distinct from B7. J Exp Med 178:1789-1793, 1993.
68. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8:1065-1072, 1997.
69. Zielask J, Hartung H-P: Molecular mechanisms of microglial activation. Adv Neuroimmunol 6:191-222, 1996.